相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations
Shingo Dan et al.
CANCER RESEARCH (2010)
PI(3)King Apart PTEN's Role in Cancer
Siyuan Zhang et al.
CLINICAL CANCER RESEARCH (2010)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding et al.
NATURE (2010)
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
Laura Poliseno et al.
NATURE (2010)
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes et al.
NATURE MEDICINE (2010)
mToR signaling and drug development in cancer
Janet Dancey
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
A. Roidl et al.
ONCOGENE (2010)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
N. Turner et al.
ONCOGENE (2010)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cell line misidentification: the beginning of the end
John R. W. Masters
NATURE REVIEWS CANCER (2010)
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Krishna M. Vasudevan et al.
CANCER CELL (2009)
PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
Robert J. Crowder et al.
CANCER RESEARCH (2009)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo
Jason T. Huse et al.
GENES & DEVELOPMENT (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Xiaolan Hu et al.
MOLECULAR CANCER RESEARCH (2009)
Everolimus
Michael B. Atkins et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
M. Pickl et al.
ONCOGENE (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
Neil E. Torbett et al.
BIOCHEMICAL JOURNAL (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells
Ilya Serebriiskii et al.
MATRIX BIOLOGY (2008)
Post-translational regulation of PTEN
X. Wang et al.
ONCOGENE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
Qing-Bai She et al.
PLOS ONE (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
Britta Weigelt et al.
SEMINARS IN CANCER BIOLOGY (2008)
Integrated profiling of basal and luminal breast cancers
Jose Adelaide et al.
CANCER RESEARCH (2007)
The third dimension bridges the gap between cell culture and live tissue
Francesco Pampaloni et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Modeling tissue morphogenesis and cancer in 3D
Kenneth M. Yamada et al.
CELL (2007)
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Gizeh Perez-Tenorio et al.
CLINICAL CANCER RESEARCH (2007)
Three-dimensional culture models of normal and malignant breast epithelial cells
Genee Y. Lee et al.
NATURE METHODS (2007)
Rare cancer-specific mutations in PIK3CA show gain of function
Marco Gymnopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
Tammie C. Yeh et al.
CLINICAL CANCER RESEARCH (2007)
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
Antoinette Hollestelle et al.
MOLECULAR CANCER RESEARCH (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
Donatella Del Bufalo et al.
CANCER RESEARCH (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunohistochemical analysis of PTEN in endometrial carcinoma:: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities
J Pallares et al.
MODERN PATHOLOGY (2005)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
MA Cobleigh et al.
SEMINARS IN ONCOLOGY (2003)
β4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium
VM Weaver et al.
CANCER CELL (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
分享论文
